Skip to content
MarketScale
‹ Back to IndustriesHealthcare

NAVIGATING THE AGILE APPROACH TO MEDICAL PRODUCT DEVELOPMENT

Engineers love to build things! Sunrise is working to keep it that way. Traditionally, development of medical products was done using a “waterfall” development process where each phase of a project builds on the previous phase to deliver exactly what was defined in requirements up front. Agile offers a more flexible approach that maintains the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Engineers love to build things! Sunrise is working to keep it that way.

Traditionally, development of medical products was done using a “waterfall” development process where each phase of a project builds on the previous phase to deliver exactly what was defined in requirements up front. Agile offers a more flexible approach that maintains the needed medical rigor, maximizes learning, and allows requirements to evolve to a more optimum solution.

As identified in AAMI TIR45:2012, the Agile approach to Medical Product development is intended to improve development in 5 basic areas:

  • Quality
  • Productivity
  • Predictability
  • Product effectiveness
  • Safety

Quality is measured during development rather than waiting until the project is complete. The Agile methodology builds the concept of “done” into the process by requiring testing as you go. This in turn, improves on productivity as the engineers who work on the project understand before approaching a task what it means to be “done.” The engineers, on a regular basis, and regardless of the stage of development, demonstrate an operational product to the “owner”.

These frequent demonstrations improve product effectiveness as the “owner” is able to see, touch, and feel the product during the entire process. This also helps to predict when and where the project is with relation to schedule and cost.

Questions concerning product safety, clinician-backed confidence, and consumer opinion are a few of many inquiries that can direct the course of a medical product’s development. Setting strict feature sets without the ability to adjust; strict schedules without the ability to adjust; and rigid budgets without the ability to adjust can be detrimental to the end goal. As a result, Agile product development has become an increasingly popular approach to developing medical products.

The Agile methodology enhances an engineer’s fundamental thought process by:

  • Decomposing large problems into manageable tasks called stories
  • Defining “Done” for each story
  • Providing better visibility for team members, management, and the client about the progress of projects
  • Consistently building products using the same process throughout the company and with all disciplines

Agile product development is customer focused. The process encourages stakeholder and developer collaboration, and bases success on the safety and efficacy efficiency of the final product. A few ways to approach this type of project management style in the development of medical devices are:

Safety and Risk

With the needs of the end user clearly identified, the solution must be designed to solve the problem at hand without undue risk and safety exposure. Risk management activities are part of the development process, and integrating risk management into product development is critical to ensure safety and efficacy. Risk mitigations are converted into requirements, and ultimately into Agile stories and managed like any other feature. These safety requirements are decomposed into manageable tasks and put into stories.

System and Software Architecture 

System and Software development is highly iterative by nature, more so when using the agile development process. Developing robust system and software architectures during the planning phases provides a proper foundation for the subsequent design phases.

Team Synergy

Collaboration among team members is essential to ensuring that product development stays on track. Knowledge barriers can be avoided when team members are aware of the bigger picture and understand where the project is and where the project is going. Agile development encourages collaboration to break down roadblocks and spur productivity. Using Agile development across the organization helps engineers and managers to coordinate activities across disciplines including electrical and mechanical engineering.

Feedback Loop

As mentioned above, demonstrations of prototypes to stakeholders in the early phases can yield valuable feedback to improve and refine the final product before costly V&V activities commence. Required usability studies for medical products by the FDA and ISO are other more formal opportunities to gather feedback. The Agile process requires the product is operational after each step in the process, ensuring working prototypes for testing.

Sunrise Solution

Developing medical products is fun. Our goal at Sunrise is to keep it that way and make it more a more predictable process that meets the customer’s needs. The Agile methodology is a powerful tool that can be utilized in the medical product development process to allow flexibility and aid in creating improved products.

Sunrise Labs has the expertise to take innovative ideas from concept to reality. The commercial medical device industry is complex and in constant flux, therefore clients leverage our expertise to overcome design challenges while satisfying regulatory requirements. At Sunrise, our passion is improving patient outcomes by helping our clients succeed in the development of beneficial medical devices.

Learn more about Sunrise Labs, our team, services, and values today.

Read more at sunriselabs.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512